• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Northwest Biotherapeutics change, expands management team

Northwest Biotherapeutics change, expands management team

June 10, 2011
CenterWatch Staff

Northwest Biotherapeutics (NWBT), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities, has added several executives to its management team.

Linda Powers, Chairman of the Board since May 2007, has been appointed Chief Executive Officer. Dr. Anthony Maida, an executive in the field of cancer immune therapies, joins as Chief Operating Officer. Dr. Alton Boynton, the scientific founder of NWBT and has served as CEO since May 2007, is returning to his position as Chief Scientific Officer. Les Goldman, a former longtime partner at Skadden, Arps specializing in advanced technology commercialization, has been appointed Senior Vice President, Business Development.

Dr. Maida brings more than 20 years of experience in building oncology companies, with expertise in the business and financial aspects, the clinical and regulatory aspects and the underlying science. He has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings. He served as CEO of CancerVax, an early leader in cancer vaccines, raising the company's first $30 million of funding. Dr. Maida also served as global head of Oncology for a CRO. He recently completed and in 2010 received a Ph.D. in Tumor Immunology. 

Goldman was a partner at law firm Skadden, Arps for over 30 years, specializing in a wide array of advanced technologies and their commercialization. He also serves as an advisor to a number of other technology companies. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing